Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Intercalated with Pemetrexed and Cisplatin in EGFR Wild-type NSCLC
NCT03374280Phase 2Unknown
- Sponsor
- Guangzhou Medical University
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Medical University. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03374280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374280.